Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 9Neoplasm Metastasis 5Stomach Neoplasms 4Biliary Tract Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Small Cell Lung Carcinoma 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Hodgkin Disease 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Recurrence 1Plaque, Atherosclerotic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Overall Survival 1Osteosarcoma 1NSCLC 1

Interventions

Gefitinib 5icotinib 4Pemetrexed 4Docetaxel 4camrelizumab 3apatinib 3anlotinib 3aflutinib 3Erlotinib Hydrochloride 3osimertinib 2dacomitinib 2Thalidomide 2Radiosurgery 2Drug Therapy 2Carboplatin 2Afatinib 2trilaciclib 1spartalizumab 1pembrolizumab 1nimotuzumab 1famitinib 1envafolimab 1Vinorelbine 1Tyrosine Kinase Inhibitors 1S 1 (combination) 1Radiofrequency Ablation 1Microphysiological Systems 1Immune Checkpoint Inhibitors 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NSCLC × Immune Checkpoint Inhibitors × Clear all
NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡